Animal Vaccines Market to reach USD 14.2 billion by 2035

The global animal vaccines market was valued at USD 14.2 billion in 2025 and is expected to grow from USD 15.2 billion in 2026 to USD 27 billion in 2035, growing at a CAGR of 6.6% during the forecast period, as per the latest report published by Global Market Insights Inc.

Expanding Livestock Industry and Food Security Concerns

The rapid expansion of the livestock industry has been driven by increasing global demand for meat, dairy, poultry, and other animal-derived products. Population growth, changing dietary preferences, and rising income levels have encouraged greater consumption of protein-rich foods, prompting farmers and producers to improve livestock productivity and efficiency. At the same time, growing concerns regarding food security have intensified the focus on maintaining healthy animal populations and maximizing agricultural output.

Increasing Pet Adoption and Expenditure on Animal Health

The rising rate of pet ownership has significantly contributed to higher spending on animal healthcare products and services. Growing recognition of pets as family companions has encouraged owners to prioritize preventive care, routine health monitoring, and advanced medical treatments for their animals. Increased awareness regarding pet wellness, longer pet life expectancy, and the availability of specialized veterinary services have further accelerated healthcare expenditure.

Stringent Regulatory Requirements

Stringent regulatory requirements have played a crucial role in shaping industry operations by establishing high standards for product quality, safety, efficacy, and environmental compliance. Regulatory authorities across various regions have implemented comprehensive guidelines governing product development, manufacturing processes, testing procedures, labeling practices, and market approvals.

Browse key industry insights spread across 142 pages with 201 market data tables and figures from the report, Animal Vaccines Market, “By Animal Type (Livestock Animals, Companion Animals), by Vaccine Type (Attenuated Live Vaccine, Conjugate Vaccine, Inactivated Vaccine, DNA Vaccine, Recombinant Vaccine, Other Vaccine Types), by Application (Bacterial Infections, Viral Infections, Parasitic Infections, Fungal Infections, Other Applications), by Route of Administration (Injection Vaccines, Oral Vaccines, Immersion/Spray Vaccines), by Distribution Channel (Veterinary Hospital Pharmacies, Retail Pharmacies, E-Commerce).” in detail, along with the table of contents:  

https://www.gminsights.com/industry-analysis/animal-vaccines-market

Livestock Animals to Gain Traction

The livestock animals segment generated USD 9.4 billion in 2025. This category includes cattle, poultry, swine, aquaculture species, sheep, and goats. The segment maintained its dominant position due to the critical role livestock production plays in the global food supply chain and agricultural economy. Animal farming remains essential to produce meat, dairy products, and eggs, making disease prevention a top priority for producers and livestock owners.

Rising Adoption of Attenuated Live Vaccines

The attenuated live vaccine segment accounted for 44% share in 2025. The segment's leadership was primarily supported by its strong clinical performance and ability to deliver long-lasting immune protection. Live attenuated vaccines remain among the most widely used veterinary vaccines available commercially due to their capability to stimulate both humoral and cell-mediated immune responses.

North America to Emerge as a Propelling Region

North America animal vaccines market held a 41.7% share in 2025 and is expected to grow at a CAGR of 6.3% during 2026-2035. Strong veterinary healthcare infrastructure, significant spending on animal health, and extensive livestock production activities have positioned North America as a major contributor to global market growth.

Key companies operating in the animal vaccines market include Boehringer Ingelheim International, Brilliant Bio Pharma, Bioveta, Ceva Santé Animale, Dechra Pharmaceuticals, Elanco Animal Health, Henry Schein Animal Health (Covetrus, Inc.), Hipra Animal Health Limited, Indian Immunologicals, Merck Animal Health, Neogen Corporation, Vetoquinol, Virbac, and Zoetis.

Companies operating in the animal vaccines market are focusing on multiple strategic initiatives to strengthen their market presence and improve competitive positioning. One of the primary strategies involves increasing investments in research and development to introduce advanced vaccines with enhanced efficacy, broader disease coverage, and longer-lasting immunity. Manufacturers are also expanding their product portfolios through new product launches and innovation in vaccine delivery technologies.

In May 2026, The Africa Centre of Excellence for Sustainable Cooling and Cold Chain (ACES) launched the Veterinary Vaccine Cold Chain Project (VETVACC), an initiative designed to enhance the storage, transportation, and distribution of animal vaccines across Rwanda.